G-Lasta (pegfilgrastim) Subcutaneous Injection 3.6 mg General use-results survey (all-case survey) -Mobilization and collection of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation-

G-Lasta (pegfilgrastim) Subcutaneous Injection 3.6 mg General use-results survey (all-case survey) -Mobilization and collection of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation- - G-Lasta (pegfilgrastim) Subcutaneous Injection 3.6 mg General use-results survey (all-case survey) -Mobilization and collection of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052251

Enrollment

350

Registered

2023-09-20

Start date

2022-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All donors who have received pegfilgrastim for the first time after the date of approval of the indication &quot

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All donors who have received pegfilgrastim for the first time after the date of approval of the indication " Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation "

Exclusion criteria

Exclusion criteria: -The contract with the facility has not been concluded -Outside the contract period with the facility -Peripheral blood stem cell collection using a daily G-CSF other than pegfilgrastim* *Registration is possible if peripheral blood stem cell collection was performed using a daily G-CSF other than pegfilgrastim in the past. -This is not the first time to collect peripheral blood stem cells by administration of pegfilgrastim -Duplicate registration (already registered)

Design outcomes

Primary

Measure	Time frame
Safety -Incidence of adverse reactions -Incidence of adverse drug reactions and infectious diseases -Examination of Safety specifications -Examination of other adverse events (headache, liver dysfunction, etc.) -Safety after peripheral blood stem cells collection -Factors that may affect safety	—

Secondary

Measure	Time frame
Efficacy -Securing the number of peripheral blood stem cells required for transplantation -Factors that may influence the evaluation of efficacy	—

Countries

Japan

Contacts

Public ContactHiroshi Kuwazawa

Kyowa Kirin Co., Ltd. Pharmacovigilance Department

hiroshi.kuwazawa.wd@kyowakirin.com+81-70-3143-9628

Outcome results